CN101687900A - 双链锁核酸组合物 - Google Patents

双链锁核酸组合物 Download PDF

Info

Publication number
CN101687900A
CN101687900A CN200880014144A CN200880014144A CN101687900A CN 101687900 A CN101687900 A CN 101687900A CN 200880014144 A CN200880014144 A CN 200880014144A CN 200880014144 A CN200880014144 A CN 200880014144A CN 101687900 A CN101687900 A CN 101687900A
Authority
CN
China
Prior art keywords
lna
formula
integer
nucleoside
analog
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880014144A
Other languages
English (en)
Chinese (zh)
Inventor
彼得·埃姆蒂奇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nventa Biopharmaceuticals Corp
Original Assignee
Nventa Biopharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nventa Biopharmaceuticals Corp filed Critical Nventa Biopharmaceuticals Corp
Publication of CN101687900A publication Critical patent/CN101687900A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CN200880014144A 2007-03-07 2008-03-07 双链锁核酸组合物 Pending CN101687900A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US90546107P 2007-03-07 2007-03-07
US60/905,461 2007-03-07
US95027107P 2007-07-17 2007-07-17
US60/950,271 2007-07-17
PCT/CA2008/000473 WO2008106803A1 (en) 2007-03-07 2008-03-07 Double-stranded locked nucleic acid compositions

Publications (1)

Publication Number Publication Date
CN101687900A true CN101687900A (zh) 2010-03-31

Family

ID=39737757

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880014144A Pending CN101687900A (zh) 2007-03-07 2008-03-07 双链锁核酸组合物

Country Status (10)

Country Link
US (1) US20090041809A1 (https=)
EP (1) EP2125853A1 (https=)
JP (1) JP2010519915A (https=)
KR (1) KR20100051041A (https=)
CN (1) CN101687900A (https=)
AU (1) AU2008222523A1 (https=)
BR (1) BRPI0808442A2 (https=)
CA (1) CA2680060A1 (https=)
MX (1) MX2009009530A (https=)
WO (1) WO2008106803A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112352052A (zh) * 2018-05-04 2021-02-09 托利斯有限公司 激活上皮细胞和髓样细胞的tlr3配体

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0228540D0 (en) * 2002-12-06 2003-01-15 Glaxo Group Ltd Novel compositions
WO2009149470A1 (en) 2008-06-06 2009-12-10 Aurora Biofuels, Inc. Vcp-based vectors for algal cell transformation
WO2009155489A2 (en) 2008-06-19 2009-12-23 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
SG10201605780QA (en) 2009-03-19 2016-09-29 Emd Millipore Corp Removal of microorganisms from fluid samples using nanofiber filtration media
US20110097418A1 (en) * 2009-05-29 2011-04-28 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
US8865468B2 (en) 2009-10-19 2014-10-21 Aurora Algae, Inc. Homologous recombination in an algal nuclear genome
US9029137B2 (en) 2009-06-08 2015-05-12 Aurora Algae, Inc. ACP promoter
US8809046B2 (en) 2011-04-28 2014-08-19 Aurora Algae, Inc. Algal elongases
US9907746B2 (en) 2009-07-06 2018-03-06 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
AU2010270722B2 (en) 2009-07-06 2015-06-04 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
US8709765B2 (en) 2009-07-20 2014-04-29 Aurora Algae, Inc. Manipulation of an alternative respiratory pathway in photo-autotrophs
EP2482824B1 (en) 2009-10-02 2016-11-30 The Trustees of Columbia University in the City of New York Piscine reovirus immunogenic compositions
US8846388B2 (en) * 2009-10-16 2014-09-30 Zoetis Llc Infectious clones of torque teno virus
CA2802721C (en) * 2010-06-25 2015-08-18 Idera Pharmaceuticals, Inc. Novel agonists of toll-like receptor 3 and methods of their use
MX342138B (es) 2010-07-06 2016-09-14 Variation Biotechnologies Inc Composiciones y metodos para el tratamiento de influenza.
ES2774949T3 (es) 2010-08-10 2020-07-23 Emd Millipore Corp Método para la eliminación de retrovirus
BR112013015797B1 (pt) 2010-12-23 2021-08-31 Shell Internationale Research Maatschappij B.V. Organismo microbiano e método de produzir um derivado de acil-coa graxo
CA2862864C (en) 2011-01-13 2018-12-11 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
CA2862871C (en) 2011-01-13 2020-09-22 Variation Biotechnologies Inc. Methods for preparing vesicles and formulations produced therefrom
US8722359B2 (en) 2011-01-21 2014-05-13 Aurora Algae, Inc. Genes for enhanced lipid metabolism for accumulation of lipids
CN105413480B (zh) 2011-04-01 2019-03-29 Emd密理博公司 含有纳米纤维的复合材料结构
MX2013012565A (es) 2011-04-28 2013-11-21 Aurora Algae Inc Desaturasas de algas.
EP2794630A4 (en) 2011-12-22 2015-04-01 Alios Biopharma Inc SUBSTITUTED PHOSPHORTHIOAT NUCLEOTIDE ANALOGUE
US20140356399A1 (en) 2012-01-12 2014-12-04 Variation Biotechnologies, Inc. Compositions and methods for treating viral infections
US20150079077A1 (en) 2012-01-27 2015-03-19 Variation Biotechnologies, Inc. Methods and compositions for therapeutic agents
WO2013142124A1 (en) 2012-03-21 2013-09-26 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
US9157101B2 (en) * 2012-12-21 2015-10-13 Algenol Biotech LLC Cyanobacterium sp. for production of compounds
AR095882A1 (es) 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
US9994831B2 (en) 2013-12-12 2018-06-12 The Regents Of The University Of California Methods and compositions for modifying a single stranded target nucleic acid
JP6568545B2 (ja) 2014-06-26 2019-08-28 イー・エム・デイー・ミリポア・コーポレイシヨン 増強された汚れ保持容量を有するフィルタ構造
WO2016061131A1 (en) 2014-10-14 2016-04-21 The J. David Gladstone Institutes Compositions and methods for reactivating latent immunodeficiency virus
MX2017008289A (es) 2014-12-23 2017-10-02 Algenol Biotech LLC Metodos para aumentar la estabilidad de la produccion de compuestos en celulas huesped microbianas.
EP3283202B1 (en) 2015-04-17 2025-10-01 EMD Millipore Corporation Method of purifying a biological materia of interest in a sample using nanofiber ultrafiltration membranes operated in tangential flow filtration mode
EP3303634B1 (en) 2015-06-03 2023-08-30 The Regents of The University of California Cas9 variants and methods of use thereof
US10138489B2 (en) 2016-10-20 2018-11-27 Algenol Biotech LLC Cyanobacterial strains capable of utilizing phosphite
EP3655142B1 (en) 2017-07-21 2026-02-25 Merck Millipore Ltd Non-woven fiber membranes
WO2019066571A2 (ko) 2017-09-28 2019-04-04 연세대학교 산학협력단 골수유래 면역반응 억제세포의 제조방법, 이에 의해 제조된 골수유래 면역반응 억제세포 및 그 용도
US12275964B2 (en) 2018-08-22 2025-04-15 The Regents Of The University Of California Variant type V CRISPR/Cas effector polypeptides and methods of use thereof
CA3117730A1 (en) 2018-11-09 2020-05-14 Inari Agriculture, Inc. Rna-guided nucleases and dna binding proteins
CA3130789A1 (en) 2019-03-07 2020-09-10 The Regents Of The University Of California Crispr-cas effector polypeptides and methods of use thereof
KR102256001B1 (ko) * 2019-07-02 2021-05-26 주식회사 엔에이백신연구소 신규한 리보핵산 및 이를 기반으로 하는 약제학적 조성물
JP2022543735A (ja) * 2019-07-02 2022-10-14 エヌエー ヴァクシン インスティテュート 新規のリボ核酸、及びそれを基にする薬剤学的組成物
WO2022036255A1 (en) * 2020-08-14 2022-02-17 Allen Institute Artificial expression constructs for modulating gene expression in striatal neurons
JP2024517181A (ja) 2021-04-28 2024-04-19 ウエヌイグレックオ・ファーマ 組合せ治療としてｆｘｒアゴニストを使用するｔｌｒ３アゴニストの効果の強い増強

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3692899A (en) * 1969-12-17 1972-09-19 Us Health Education & Welfare Inhibition of transplanted tumor growth by polyinosinic-polycytidylic acid in mice
US3952097A (en) * 1974-09-27 1976-04-20 The United States Of America As Represented By The Department Of Health, Education And Welfare Nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid
US4024241A (en) * 1974-09-27 1977-05-17 The United States Of America As Represented By The Secretary Of Health, Education And Welfare Nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid
US4349538A (en) * 1979-12-07 1982-09-14 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid
ATE509102T1 (de) * 1994-07-15 2011-05-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7157089B1 (en) * 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
JP3756313B2 (ja) * 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
CA2203843C (en) * 1997-04-28 2013-07-23 Her Majesty The Queen, In Right Of Canada, As Represented By The Ministe R Of National Defence Liposome-encapsulated poly iclc
US6794499B2 (en) * 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US6083482A (en) * 1999-05-11 2000-07-04 Icn Pharmaceuticals, Inc. Conformationally locked nucleosides and oligonucleotides
AT410173B (de) * 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
EP1474432A1 (en) * 2002-02-04 2004-11-10 Biomira Inc. Immunostimulatory, covalently lipidated oligonucleotides
EP1778186B1 (en) * 2002-07-03 2011-11-30 Oncovir, Inc. Method for preparation of poly-iclc and uses thereof
GB0228540D0 (en) * 2002-12-06 2003-01-15 Glaxo Group Ltd Novel compositions
EP2508608A1 (en) * 2003-06-09 2012-10-10 Alnylam Pharmaceuticals Inc. Method of treating neurodegenerative disease
CA2587676A1 (en) * 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna
US7834064B2 (en) * 2005-01-03 2010-11-16 Andres Mario Salazar Clinical method for the immunomodulatory and vaccine adjuvant use of poly-ICLC and other dsRNAs
CA2626977A1 (en) * 2005-10-27 2007-05-03 Rosetta Inpharmatics Llc Nucleic acid amplification using non-random primers
EP2202239A1 (en) * 2005-11-01 2010-06-30 Alnylam Pharmaceuticals Inc. RNAI inhibition of influenza virus replication

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112352052A (zh) * 2018-05-04 2021-02-09 托利斯有限公司 激活上皮细胞和髓样细胞的tlr3配体

Also Published As

Publication number Publication date
MX2009009530A (es) 2010-05-19
KR20100051041A (ko) 2010-05-14
CA2680060A1 (en) 2008-09-12
JP2010519915A (ja) 2010-06-10
BRPI0808442A2 (pt) 2014-08-05
AU2008222523A1 (en) 2008-09-12
EP2125853A1 (en) 2009-12-02
US20090041809A1 (en) 2009-02-12
WO2008106803A1 (en) 2008-09-12

Similar Documents

Publication Publication Date Title
CN101687900A (zh) 双链锁核酸组合物
US20110038888A1 (en) Adjuvant compositions comprising poly-ic and a cationic polymer
ES2526879T3 (es) Composiciones y procedimientos para formulaciones de oligonucleótidos
CN1604795B (zh) 具有提高的活性的组合基序免疫刺激寡肽
ES2380796T3 (es) Oligonucleótidos inmunoestimuladores y sus usos.
CN101460620B (zh) 免疫刺激寡核苷酸及其药物用途
ES2265980T3 (es) Metodos relacionados con interferon inducido por acidos nucleicos inmuoestimuladores.
EP1278761B1 (en) MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES
Agrawal et al. Mixed backbone oligonucleotides: improvement in oligonucleotide-induced toxicity in vivo
AU2001245627B2 (en) Immunostimulatory polynucleotide sequences for use in preventing and treating viral infections
CN101052643B (zh) 抑制先天免疫应答和自身免疫的方法和组合物
US7176296B2 (en) Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
US7105495B2 (en) Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
CN101541965A (zh) Tlr配体与抗病毒剂的组合物
JP2004509970A5 (https=)
JP2006512927A (ja) ５’ｃｐｇ核酸およびその使用方法
AU2018247308A1 (en) Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
JP5359883B2 (ja) 肝炎の治療剤又は予防剤
JP5415724B2 (ja) 一種のオリゴヌクレオチド及びその応用
WO2006108358A1 (en) ANTIVIRAL USE OF ARTIFICIAL CpG-CONTAINING SINGLE-STRANDED OLIGODEOXYNUCLEOTIDES IN COMBINATION WITH RIBAVIRIN
CN112322626A (zh) 一种对PRRSV具有特异性免疫刺激作用的CpG-ODN及其应用
WO2022094102A1 (en) Immunostimulatory oligonucleotides for the prevention and treatment of covid-19
JP2014073126A (ja) 一種のオリゴヌクレオチド及びその応用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20100331